Valeo Pharma Inc. (VPHIF) Income Statement Analysis

See more : SOFT99corporation (4464.T) Income Statement Analysis – Financial Results

Complete financial analysis of Valeo Pharma Inc. (VPHIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valeo Pharma Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Wieson Technologies Co., Ltd. (6272.TWO) Income Statement Analysis – Financial Results
PT Semacom Integrated Tbk (SEMA.JK) Income Statement Analysis – Financial Results
SpectrumOne AB (publ) (SPEONE.ST) Income Statement Analysis – Financial Results
Qianhe Condiment and Food Co., Ltd. (603027.SS) Income Statement Analysis – Financial Results
ALT Telecom Public Company Limited (ALT.BK) Income Statement Analysis – Financial Results

Valeo Pharma Inc. (VPHIF)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.valeopharma.com

About Valeo Pharma Inc.

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.

Metric	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	53.91M	27.75M	13.56M	7.47M	6.58M	4.38M	1.28M	985.71K
Cost of Revenue	40.83M	21.46M	9.60M	6.09M	5.18M	3.55M	747.09K	2.35M
Gross Profit	13.08M	6.28M	3.96M	1.38M	1.40M	832.97K	530.40K	-1.37M
Gross Profit Ratio	24.26%	22.64%	29.17%	18.49%	21.30%	19.01%	41.52%	-138.68%
Research & Development	0.00	0.00	0.00	0.00	8.00K	0.00	126.26K	0.00
General & Administrative	22.56M	18.81M	13.31M	3.32M	3.04M	2.98M	2.84M	1.10M
Selling & Marketing	6.59M	6.09M	2.89M	2.12M	2.01M	236.53K	133.75K	72.75K
SG&A	29.15M	24.90M	16.19M	5.45M	5.05M	3.22M	2.98M	1.01M
Other Expenses	1.15M	0.00	123.00K	198.00K	253.00K	147.04K	50.77K	0.00
Operating Expenses	30.31M	25.39M	16.65M	5.68M	5.14M	3.26M	3.14M	1.01M
Cost & Expenses	71.14M	46.86M	26.25M	11.77M	10.31M	6.81M	3.89M	3.36M
Interest Income	3.72M	173.00K	1.00K	1.00K	0.00	816.00	368.00	114.17K
Interest Expense	13.79M	6.46M	1.36M	598.00K	110.00K	173.85K	102.42K	0.00
Depreciation & Amortization	2.63M	1.42M	743.00K	424.00K	135.00K	44.47K	40.12K	38.56K
EBITDA	-11.39M	-17.56M	-11.86M	-3.74M	-3.41M	-2.33M	-2.55M	-2.34M
EBITDA Ratio	-21.13%	-63.28%	-87.47%	-49.44%	-51.85%	-53.13%	-199.81%	-237.24%
Operating Income	-17.23M	-19.60M	-12.94M	-4.12M	-3.55M	-2.37M	-2.59M	-2.38M
Operating Income Ratio	-31.96%	-70.66%	-95.45%	-55.11%	-53.90%	-54.15%	-202.95%	-241.15%
Total Other Income/Expenses	-10.58M	-7.32M	-1.42M	-644.00K	122.00K	28.00K	-1.86M	460.53K
Income Before Tax	-27.81M	-26.92M	-14.23M	-4.76M	-3.62M	-2.40M	-4.50M	-1.92M
Income Before Tax Ratio	-51.58%	-97.03%	-104.99%	-63.73%	-54.96%	-54.78%	-352.25%	-194.43%
Income Tax Expense	0.00	-1.17M	1.48M	796.00K	326.00K	36.72K	-881.21K	-640.00K
Net Income	-27.81M	-25.75M	-14.23M	-4.76M	-3.62M	-2.44M	-3.62M	-1.28M
Net Income Ratio	-51.58%	-92.80%	-104.99%	-63.73%	-54.96%	-55.62%	-283.27%	-129.50%
EPS	-0.32	-0.32	-0.20	-0.08	-0.07	-0.05	-0.07	-0.03
EPS Diluted	-0.32	-0.32	-0.20	-0.08	-0.07	-0.05	-0.07	-0.03
Weighted Avg Shares Out	86.12M	80.86M	69.93M	57.91M	49.59M	48.47M	48.47M	44.90M
Weighted Avg Shares Out (Dil)	86.12M	80.86M	69.93M	57.91M	49.59M	48.47M	48.47M	44.90M

Valeo Pharma adds chief development officer to drive growth initiatives

June 18, 2024proactiveinvestors.com

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) announced that Al Moghaddam will be taking up the newly created role of chief development officer and, as a result will be stepping down from the company's board of directors. The Canadian pharmaceutical company said that as...

Valeo Pharma sees record 2Q revenue boosted by respiratory products and core brand growth

June 14, 2024proactiveinvestors.com

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) saw revenue for the second quarter of 2024 increase primarily driven by successful promotional activities for respiratory products, increased sales of Allerject, and continued growth in other core products like Redesca and Simbrinza. In its...

Valeo Pharma restructures field operations to save over $5m annually

June 13, 2024proactiveinvestors.com

Valeo Pharma Inc said it has launched a restructuring of its field sales operations, taking cost-cutting to more than $7 million a year, including other recent measures. The latest initiative, which includes a 20% reduction of the workforce, aims to improve...

Valeo Pharma taps life sciences leader for board position

March 22, 2024proactiveinvestors.com

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has announced the appointment of Al Moghaddam to its board of directors. The Kirkland, Quebec-based pharmaceutical company highlighted that Moghaddam brings more than 25 years of global experience as a customer-centric transformational life sciences leader...

Valeo Pharma sees 1Q revenue increase on strong performance from respiratory division

March 15, 2024proactiveinvestors.com

Canadian pharmaceutical company Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) reported a 3% increase in first quarter revenue compared to the same period in the previous year driven by strong sales from its respiratory business unit. For the first quarter ending January...

Valeo Pharma unveils boardroom reshuffle

February 13, 2024proactiveinvestors.com

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) announced a boardroom reshuffle that includes the addition of two new members and the departure of four. Robert Raich and Charles Bisaillon have joined as directors, bringing with them significant senior-level experience.

Valeo Pharma amends Novartis eye treatment distribution agreement

February 5, 2024proactiveinvestors.com

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has unveiled changes to a seven-year agreement with Novartis Pharmaceuticals for the distribution of its eye treatment. Xiidra, a treatment for dry eye, will be distributed by Valeo until late this year, rather than for...

Valeo Pharma achieves record revenues for fiscal 2023

January 30, 2024proactiveinvestors.com

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record revenues of $54 million for fiscal 2023, representing a 94% year-over-year increase driven by increased demand for its prescription products. The Canadian pharmaceutical company also posted a record adjusted gross profit of $16.9 million...

Valeo Pharma announces cost-reduction initiatives as it welcomes new CFO

November 20, 2023proactiveinvestors.com

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) told investors it expects to cut its operating expenses by more than $2 million a year by streamlining its organizational structure and commercial support activities. The series of initiatives are aimed at driving operational efficiency...